Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biomerica (BMRA) EBITDA Margin (2016 - 2026)

Biomerica's EBITDA Margin history spans 17 years, with the latest figure at 132.93% for Q1 2026.

  • Quarterly results put EBITDA Margin at 132.93% for Q1 2026, down 2891.0% from a year ago — trailing twelve months through Feb 2026 was 96.28% (down 1067.0% YoY), and the annual figure for FY2025 was 93.69%, up 1656.0%.
  • EBITDA Margin for Q1 2026 was 132.93% at Biomerica, down from 109.17% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 0.29% in Q3 2025 to a low of 205.07% in Q2 2025.
  • The 5-year median for EBITDA Margin is 109.17% (2025), against an average of 102.59%.
  • The sharpest move saw EBITDA Margin soared 12888bps in 2022, then tumbled -14847bps in 2023.
  • Year by year, EBITDA Margin stood at 110.32% in 2022, then rose by 13bps to 96.17% in 2023, then skyrocketed by 39bps to 58.31% in 2024, then plummeted by -87bps to 109.17% in 2025, then fell by -22bps to 132.93% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 132.93%, 109.17%, and 0.29% for Q1 2026, Q4 2025, and Q3 2025 respectively.